Introduction
During the past decade, our understanding of the biology underlying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has improved tremendously. Both diseases are characterized by enormous biological and clinical heterogeneity, which is based on the accumulation of a variety of somatically acquired genetic aberrations in hematopoietic progenitor and/or stem cells (HPCs/HSCs), resulting in altered cell growth and differentiation. [1] [2] [3] Today, cytogenetics still represents one of the most powerful prognostic factors in MDS and AML, with clonal chromosomal alterations detected in many MDS (B50%) and AML (B55%) patients at diagnosis. Furthermore, the incorporation of molecular genetic assays into diagnostic workflows has revealed numerous gene mutations that allowed further classification of MDS and AML into molecularly distinct subclasses. For example, in the large group of AML patients with cytogenetically normal AML (CN-AML), aberrations such as internal tandem duplications (ITD) of the FLT3 gene, as well as mutations of CEBPA and NPM1 have been shown to be of prognostic relevance, and the latter two molecular aberrations have recently been added as provisional entities into the current World Health Organization classification guidelines. 4 However, the heterogeneity of MDS and AML is still not fully reflected by the current classification systems.
The advancement of genomics technologies has offered a range of experimental approaches to capture the molecular variation underlying the biological and clinical heterogeneity of MDS/AML. For example, microarray-based gene expression profiling (GEP) has been shown to be a very powerful tool that has been applied successfully in several MDS and AML studies (Table 1 ). In a milestone study, Golub et al. 5 were able to distinguish AML and acute lymphoblastic leukemia (ALL) patients without previous knowledge of the respective leukemia classes. Significantly, this study for the first time demonstrated the power of GEP to predict known leukemia classes, and even to discover novel leukemia subclasses.
In this study, we provide a comprehensive review on the impact of GEP on MDS and AML over the last decade. The first sections focus on AML and MDS studies in adults and children, and discuss how GEP has helped (i) to identify characteristic gene expression patterns in MDS/AML subclasses, with specific cytogenetic and/or molecular genetic aberrations (class prediction), (ii) to discover novel leukemia subclasses (class discovery) and (iii) to predict response to standard therapy in both MDS and adult as well as pediatric AML (outcome prediction). 6, 7 The final sections review potential applications of GEP including the prediction of drug response, drug discovery and future integrative data analysis approaches that will not only allow a refined patient management, but also provide deeper insights into the molecular mechanisms underlying MDS and AML. 
GEP in adult AML
During the last years, GEP studies have shown that many cytogenetic or molecular genetic aberrations in AML are characterized by distinct gene expression profiles that, for some subclasses, even allow highly accurate prediction of the respective aberrations and can confer prognostic information independent of known genetic risk factors. Furthermore, analysis of altered gene expression can point to yet unknown molecular mechanisms underlying leukemogenesis, and thereby contribute further to the refinement of the molecular classification of AML. 8, 9 Although in the early days it was sometimes doubted whether GEP could produce reproducible results, there is now strong evidence from numerous AML studies that GEP technology can easily be standardized for diagnostics, in as much distinct gene expression patterns are quite robust with respect to both high intra-and inter-platform comparability. [10] [11] [12] [13] [14] Thus, GEP has been successfully applied to improve the molecular classification of AML. For example, genomics-based prediction of known leukemia classes (class prediction) has been shown to be feasible for well-defined cytogenetic AML subclasses of the World Health Organization classification guidelines such as AML with translocation t(8;21), inversion inv(16), t(15;17) and various translocations involving MLL (these are referred to as AML with t(11q23)/MLL rearrangements and include: AML with t(9;11)(p22;q23)/MLLT3-MLL; t(6;11)(q27;q23)/MLLT4-MLL; t(11;19) (q23;p13.3)/MLL-MLLT1; t(11;19)(q23;p13.1)/MLL-ELL; and t(10;11)(p12;q23)/MLLT10-MLL), thereby providing a powerful novel diagnostic tool. For example, the international multi-centre research program (MILE Study) centered around the European Leukemia Network (ELN, http://www.leukemia-net.org) performed a powerful exploratory retrospective stage I study, designed for biomarker discovery based on whole-genome expression profiles from 2143 patients with various types of chronic and acute leukemias as well as MDS. This stage I study was followed by a prospective stage II study validating the diagnostic accuracy of the GEP-based classifiers in an independent cohort of 1191 patients. 15, 16 On the basis of 2096 patients, which included 542 AML cases, the stage I study achieved 92.2% classification accuracy and a median specificity of 99.7% for 18 distinct types of leukemias including AML with complex aberrant karyotype, CN-AML, t(11q23)/MLL-rearrangement, t(8;21), inv (16) and t (15;17) . In accordance, in the second prospectively collected cohort of 1152 patients the classification scheme for AML and ALL cases reached a median sensitivity and specificity of 95.6 and 99.8%, respectively. 16 Recently, multicenter trials have also demonstrated that distinct molecular aberrations in AML such as mutations of the NPM1 and CEBPA genes can be reliably diagnosed based on resulting characteristic gene expression signatures (Figure 1 ). Interestingly, such gene expression signatures can also provide additional molecular insights as exemplified by the identification of the role of deregulated FLT3 expression in t(11q23)/MLLrearranged leukemia, and might therefore better capture the underlying disease biology. 19 For example, in CN-AML patients predicted to have a FLT3-ITD mutation based on the resulting gene expression patterns, the class prediction profiles outperformed the presence of the molecular marker FLT3-ITD with regard to impact on clinical outcome. 20 Furthermore, in CEBPAmutated CN-AMLs, only CEBPA double mutants, but not single mutants, seem to exhibit a characteristic gene expression profile. 21 In addition to its role in class prediction, GEP has proved to be a very powerful means for the discovery of novel leukemia subclasses (class discovery). Initial studies screening large AML cohorts identified novel biologically and clinically meaningful subclasses, primarily through discovery of novel subclasses among the heterogeneous cohort of CN-AML cases. 22, 23 Notably, a cohort of AML patients with a gene expression signature resembling CEBPA-mutated CN-AML were found to exhibit epigenetic silencing of CEBPA expression through hypermethylation of its promoter. 24 Similarly, the identification of KIT wild-type core-binding factor AMLs harboring expression profiles similar to KIT-mutated core-binding factors suggests that different leukemogenic events can result in the activation and deregulation of identical sets of genes and/or oncogenic pathways. 25 In accordance, gene expression signatures have been identified that reflect the heterogeneous clinical response of both CN-AML and core-binding factor AML, thereby providing further evidence that GEP-based outcome prediction in AML is feasible and can provide information in addition to cytogenetics and molecular genetics. 22, 26 To discover gene expression signatures of prognostic value, a recent proof-of-principle study successfully applied a novel strategy including a combination of supervised and unsupervised data analysis and defined a 133-gene signature. Subsequent validation demonstrated the 133-gene signature to be a significant independent outcome predictor, both across all cytogenetic AML subclasses and within CN-AML cases. 22 Importantly, the prognostic significance of these results was also confirmed by different study groups in independent AML cohorts despite several significant study differences including microarray platforms and patient treatment protocols. 27, 28 To increase the potential clinical applicability, Radmacher et al. 27 created a class-prediction algorithm allowing outcome prediction for individual patients, and recently GEP-based outcome prediction was further refined in large CN-AML cohorts. 22, 26, 27, 29 Although these findings are encouraging and ongoing studies analyzing large patient cohorts are aiming to validate and improve CN-AML-specific classifiers, the rapid pace at which novel molecular markers of prognostic relevance are currently identified in AML reduces the rate of development of GEP-based outcome signatures that are truly independent of known molecular markers. In this study, an accurate outcome prediction signature that no longer needs to be independent of these markers, but has the ability to capture the prognostic impact of all possible marker combinations in a single measurement, might represent a valuable alternative to multiplex sequencing of the plethora of currently known molecular markers. This approach is particularly intriguing in as much irrelevant passenger mutations are unlikely to affect outcome prediction, whereas so-called driver mutations that are functionally and prognostically relevant will have a major impact on the gene expression profiles.
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GEP in pediatric AML
Like adult AML, pediatric AML represents a heterogeneous disease where prognosis correlates with early therapy response, and cytogenetic as well as molecular genetic aberrations. Although current overall survival rates of pediatric AML patients are as high as 60%, further improvement is hampered by considerable short-and long-term toxicity of current therapeutic regimens. Thus, in pediatric AML, GEP studies have been performed with identical aims as described for in adult AML.
In a seminal study of 130 de novo pediatric AML patients, Ross et al. 30 successfully identified class-discriminating gene expression signatures for ALL and AML. 30 Likewise, the major prognostic AML subclasses, that is, t(15;17), t(8;21), inv(16) and t(11q23)/MLL, as well as cases classified as acute megakaryoblastic leukemia (cases exhibiting a FAB M7 morphology) were predicted with an overall classification accuracy greater than 93% using supervised learning algorithms. This high classification accuracy for the respective AML subclasses was confirmed and extended in an independent study of 237 children with pediatric AML (specificity and sensitivity for discovery of the indicated cytogenetic subclasses was 99 and 100%, respectively). 31 In contrast to adult AML, no general predictive gene expression signatures were found for the molecular genetic aberrations NPM1, CEBPA, FLT3-ITD or KIT in pediatric AML. However, distinct gene expression signatures were discovered for FLT3-ITD in t(15;17) and CN-AML. 31 Significantly, these studies demonstrate the potential of GEP in terms of class prediction also in childhood leukemia. Additionally, they indicate that gene expression profiles associated with specific genetic aberrations might be influenced by the cell lineage and maturation stage of the leukemia subclass, which in turn is most likely influenced by a specific combination of yet unknown genetic and epigenetic aberrations.
Nevertheless, recent studies have shown the potential to identify unique signatures for distinct genetic aberrations independently of the cellular context. For example, a combined analysis of a large series of ALL and AML patients identified a common gene expression signature for leukemias with MLL chimeric fusion genes irrespective of their lineage association, whereas AMLs with partial tandem duplications of the MLL gene (MLL-PTD) failed to cluster with those leukemias having MLL chimeric fusion genes. 19, 30, 31 Another unsupervised study of 237 de novo pediatric AMLs showed profound clustering of the known relevant cytogenetic subgroups (Figure 2) . 31 Moreover, it was recently shown that high VEGFC expression is associated with unique gene expression profiles, and predicts adverse prognosis in pediatric as well as adult AML. 32 In addition to class prediction and discovery, prognostic gene expression signatures have also been reported in pediatric AML. For example, Bresolin et al. 33 showed non-AML-like and AMLlike gene expression signatures discriminating juvenile myelomonocytic leukemia, with the AML-like signature being significantly associated with adverse outcome. Similarly, investigation of pediatric AML patients with FLT3-mutations allowed the identification of a RUNX3 to ATRX expression ratio that correlated with outcome, irrespective of the FLT3 mutation status, 34 and a small study in pediatric acute myelomonocytic leukemia (characterized by FAB M4/M5 morphology) revealed age-associated gene expression differences that might be associated with outcome. 35 Thus, like in adult AML, results of pediatric studies hold great promise that GEP-based prognostication is feasible.
In line with these findings, novel information on the molecular pathomechanisms underlying pediatric AML can be uncovered by GEP. For example, pediatric MDS and MDS-related AML showed differential expression of genes related to endocytosis and protein transport. 36 Also, similarly as in adult AML, NPM1-mutated pediatric AML was associated with deregulation of homeobox genes, which significantly differed from HOX gene deregulation in MLL-rearranged pediatric AML, thereby suggesting for the first time different routes of perturbed HOX gene expression in pediatric AML subclasses. 37 Insights into the function of leukaemia-associated antigens were recently gained from investigating the biology of PRAME (preferentially expressed antigen of melanoma) in pediatric AML showing PRAME-positive cases to harbor an increased expression of genes encoding ABC transporters, such as multidrug resistance proteins and decreased expression of genes encoding apoptotic proteins. 38 And recently like in adult AML, 24 co-clustering of CEBPA-mutated AML with CEBPA wildtype samples identified promoter hypermethylation-based CEB-PA silenced cases. 31 Thus, in both adult and pediatric AML, GEP studies have proven to be of value for class prediction, class discovery, outcome prediction and the identification of novel biological insights. However, especially in pediatric AML, the value of diagnostic and prognostic signatures needs confirmation. Given the rarity of pediatric AML, prospective studies of larger cohorts will require international collaborations. In this study, the COST (Cooperation in Science and Technology)-sponsored action EuGESMA (The European Genomic and Epigenetic Study on MDS and AML) as well as the European LeukemiaNet (ELN) can provide such collaborative networks of excellence (see http:// www.qub.ac.uk/research-centres/EuGESMA/ and http://www. leukemia-net.org/content/home/).
GEP in MDS
In contrast to the wealth of GEP data for most leukemia and lymphoma entities, the MDS have not been analyzed extensively, yet. The heterogeneity of MDS has been seen as a disadvantage for GEP-based classifications, but several studies have compared gene expression profiles between MDS and healthy individuals, between different stages of MDS or between MDS-derived AML and de novo AML (Figure 3) . [39] [40] [41] [42] Most of these studies have been based on CD34 þ or CD133 þ cell populations isolated from normal/healthy and MDS bone marrow providing valuable insights into the molecular pathomechanisms of MDS. However, other studies have proven that it is also feasible to use unfractionated mononuclear bone marrow cells to identify diagnostic or prognostic molecular signatures. 16, 43 With regard to biological insights, an early study analyzing CD34 þ MDS cells (n ¼ 55) revealed expression profiles similar ). 41 Interestingly, distinct gene expression profiles were associated with specific FAB and cytogenetic subclasses and CD34 þ cells from patients with refractory anemia with ringed sideroblasts were characterized by deregulation of mitochondrial-related genes. Subsequent studies investigating ringed sideroblasts showed that expression of the iron transporter ABCB7 was low in ringed sideroblasts patients and observed a strong relationship between increasing percentage of bone marrow ring sideroblasts and decreasing ABCB7 gene expression levels, 44 and confirmed the deregulation of mitochondrial function or integrity genes. 45 Investigation of the MDS subgroup with loss of the long arm of chromosome 5 (5qÀ) also provided novel insights. Comparison of 5qÀ MDS stem cells versus normal HSCs (CD34 þ , CD38À and Thy1 þ ) showed the upregulation of a number of significant genes in 5qÀ stem cells: BMI1 (which is known to have a role in HSC and neural stem cell self-renewal), ID1 (which is involved in preventing the premature differentiation of HSCs and ES cells), DNMT3A (which is involved in DNA methylation regulation) and MYC (which has a role in stem cell regulation). 46 Expression of CEBPA, encoding a myeloid transcription factor, was also upregulated in the 5qÀ stem cell fraction, but downregulated in 5qÀ progenitor cells (CD34 þ , CD38 þ and Thy1À) compared with normal HSCs and HPCs, respectively. Other studies have reported haploinsufficiency of the tumor suppressor genes SPARC and RPS14, a component of the 40S ribosomal subunit, in patients with 5qÀ syndrome. 47, 48 Interestingly, similarities in the defective gene expression patterns observed in the CD34 þ cells of patients with Diamond Blackfan anemia and patients with the 5qÀ syndrome were recently demonstrated, including the downregulation of multiple ribosomal genes and genes involved in translation initiation, suggesting that the 5qÀ syndrome represents a disorder of aberrant ribosome biogenesis. 47 Downregulation of multiple ribosomal genes in MDS patients with the 5qÀ has been confirmed recently. 49 In general, GEP analysis of a large cohort of CD34 þ MDS cell samples (n ¼ 183) revealed the most deregulated gene pathways to be interferon signaling, thrombopoietin signaling and the Wnt pathways. 50 Early MDS stages showed deregulation of immunodeficiency, apoptosis and chemokine signaling pathways, whereas advanced MDS was characterized by deregulation of DNA damage response and checkpoint pathways. Distinct gene expression profiles and deregulated gene pathways were identified in patients with 5qÀ, trisomy 8 or À7/ del(7q). The deregulated pathways identified in MDS illuminate the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention. 50 Further and larger studies, mainly on AML patients, showed that it is possible to identify existing classification groups, but also showed that some of the GEP-derived subclasses could be correlated to clinical outcome. 22, 23, 51 However, these studies also highlighted the need for a large multi-center comparison of GEP-based diagnosis with standard diagnostics as a global approach to leukemia classification. 15 In this study, the MILE study assessed the application of a microarray test using unfractionated bone marrow and its potential for use in the diagnosis and sub-classification of acute and chronic leukemia subclasses, including MDS. 16 However, unlike for AML, in the early stages the diagnostic classifier correctly identified only B50% of the unfractionated MDS specimens submitted to the MILE study. The prediction results of the other samples were split approximately equally between 'none of the target classes' and AML signatures. Interestingly, this distinction was reflected in clinical outcome in terms of a highly significant correlation with GEP-based classification (MDS, AML or 'normal') and time to AML transformation. 43 Notably, the performance of this diagnostic classifier was not directly correlated with the amount of blast cells in the sample indicating that this morphological feature is only a proxy for the aggressiveness of the stage of disease, and further indicating that the current classification needs to be further refined. Furthermore, an improved prognostic classifier was developed that had a very high correlation with both time to AML transformation and overall survival. 43 The prognostic classifier included 'AML-associated' genes, including HOXA9, KIT, NPM1 and WT1, whose expression correlated with the transformation process. The predictive value of gene expression signatures was also confirmed using marrow CD34 þ cells from MDS patients. 49 In this study, a 'poor risk' signature associated with AML transformation was shown to be enriched for 'ribosomal', MYC and WNT signaling targets. 49 Overall, the analysis of MDS subclasses, diagnostics approaches and outcome prediction have been less advanced than for AML and ALL. This is due to the wide variation in numbers of blast cells and has led to two directions of analysis. Sub-population analysis of sorted immature cell populations has identified a series of genes probably related to the pathophysiology of the disease subclasses, whereas the analysis of unfractionated BM has been valuable to characterize disease classification and prognosis. Both the directions will contribute now to the molecular understanding of disrupted gene expression in MDS, which forms the basis for improved MDS therapy and patient outcome.
GEP in MDS and
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GEP-based prediction of drug response or resistance
Recently, GEP has been successfully applied to predict response or resistance to different therapeutic modalities in various cancer entities including leukemia. This is of great importance as in addition to the currently used cytotoxic standard chemotherapy regimens in AML, there is increasing evidence for the potential of drugs that can overcome the differentiation block of AML cells. The huge potential of differentiation therapy is particularly striking in acute promyelocytic leukemia (APL), where therapeutic regimens including all-trans-retinoic acid (ATRA) and more recently arsenic trioxide have improved the clinical outcome significantly. 52, 53 This tremendous success of differentiation therapy in APL has raised the question whether AML subclasses other than APL might respond to differentiation therapy, a scenario supported by recent studies demonstrating an ATRA response in non-APL AML. [54] [55] [56] However, differentiation following ATRA treatment seems to be restricted to a subgroup of non-APL AML, which might be predicted by GEP. [57] [58] [59] In an elegant GEP study, Tagliafico et al. 60 used AML cell lines and defined a gene expression signature capable to predict ATRA-mediated differentiation of 28 primary AMLs in-vitro. To further validate the identified ATRA response signature in a clinical context, they generated a clinical ATRA response signature using GEP data from the AMLSG Trial HD98B, which recently demonstrated that ATRA administered after intensive chemotherapy significantly improved the outcome of older non-APL AML patients. 61 Strikingly, a supervised analysis showed an overlap of genes contained within both the clinical-and the in-vitro ATRA response signatures (Tagliafico E, unpublished observations). Importantly, the latter indicates a certain robustness of ATRA response signatures as in-vitro signatures based on ATRA treatment alone, and clinical signatures reflecting a synergistic effect of both ATRA and chemotherapy share a distinct set of genes (Tagliafico E, unpublished observations).
Consistent with these findings, other studies have demonstrated the potential of GEP to predict response or resistance of MDS/AML to specific drugs. For example, in an attempt to identify patients likely to respond to treatment with a farnesyltransferase inhibitor, Raponi et al. 28 analyzed gene expression profiles of bone marrow samples from elderly and previously untreated AML patients enrolled in a phase II trial investigating the farnesyltransferase inhibitor tipifarnib as single agent. Comparison of gene expression profiles from responders (that is patients with complete remission and hematologic improvement) and non-responders (that is patients with progressive disease) identified a 2-gene classifier, the RASGRP1/ APTX gene expression ratio, which was highly predictive of farnesyltransferase inhibitor response (sensitivity, 92.3%; specificity, 100%; negative predictive value, 92.9%; positive predictive value, 100%). Subsequent validation using quantitative PCR and an independent data set of gene expression profiles obtained from relapsed or refractory AML patients treated with single agent tipifarnib confirmed the predictive power of the identified RASGRP1/APTX classifier in terms of farnesyltransferase inhibitor response. 28 Another study exemplifying the successful use of GEP to predict response to novel drugs aimed to predict a lenalidomide (revlimid) response in MDS lacking a 5q deletion, as lenalidomide treatment not only has demonstrated significant clinical response in 5qÀ MDS but also in a minority of MDS patients lacking 5q deletions. 62, 63 In a seminal study, Ebert et al.
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compared responder and non-responder gene expression profiles from non-5qÀ MDS patients and identified genes associated with lenalidomide response. Notably, the identified lenalidomide response signature contained primarily genes specific to the erythroid differentiation program, which was markedly downregulated or absent in responders compared with non-responders. Consistent with this finding lenalidomde not only induced the observed response signature in CD34 þ cells from healthy subjects, but also promoted their erythroid differentiation. Additional validation using an independent data set confirmed the predictive power of the lenalidomide response signature for both MDS patients with and without 5q deletions. 64 The latter indicates that a distinct molecular phenotype in MDS, that is absence of erythroid differentiation, predicts clinical response to lenalidomide.
Taken together, identification of drug response signatures by GEP holds great promise as a powerful tool for the stratification of MDS/AML patients to specific treatment modalities. Moreover, the correlation of drug response signatures from clinical trials and in-vitro studies suggests that the assessment of drug responsiveness in individual MDS/AML patients using in-vitro assays might be feasible in the near future. However, transferring the potential of GEP into therapeutic benefits for MDS/AML patients represents a highly demanding task that will require prospective GEP within large clinical trials.
GEP as a tool for identification of drugs with therapeutic potential in AML
AML emerges as a consequence of accumulating independent genetic aberrations that direct deregulation and/or dysfunction of genes resulting in abnormal activation of signaling pathways, resistance to apoptosis and uncontrolled proliferation. 65, 66 So far more than 100 genetic aberrations presenting in various combinations have been identified in AML. 3, 4 Consistent with this considerable heterogeneity of AML genomes, AML patients demonstrate highly variable clinical responses to conventional therapeutic regimens consisting of a cytarabine and anthracycline backbone. 4, 65 Although the response to current and novel therapeutic approaches can already be predicted by GEP, the current clinical situation calls also for the development of more effective therapies that specifically target deregulated genes and/ or pathways of either distinct subclasses of AML or, at best, individual AML patients.
As discussed in the previous sections, GEP studies have demonstrated that AML gene expression profiles correlate well with specific genetic aberrations and can predict clinical outcome. In other words, gene expression profiles represent genomic surrogates of distinct biological phenotypes that emerge as a consequence of specific combinations of genetic aberrations. Significantly, gene expression profiles also provide encrypted information on those genes and pathways that are deregulated and contribute to malignant transformation. Consistent with these findings, recent studies have demonstrated the feasibility of translating genomic information provided by cancer gene expression profiles into targeted therapy. A most elegant study conducted by Chang et al. 67 defined gene expression signatures that correlated with activity of oncogenic pathways. Significantly, Chang et al. demonstrated that signatures for RAS, E2F and EGFR pathways allowed classification of distinct cancer entities, and were predictive for clinical outcome and response to pathway-specific drugs. Two other studies applied gene expression signatures that are associated with the inhibition of leukemic cell proliferation and viability. In one study, Corsello et al. 68 defined a signature for RUNX1-RUNX1T1 (AML1-ETO) inhibition by comparing gene expression profiles of a leukemia cell line harboring the t(8;21) translocation before and after RNAi-mediated knockdown of RUNX1-RUNX1T1. Subsequently, the RUNX1-RUNX1T1 inhibition signature was matched with a library of drug expression signatures, which identified corticosteroids and dihydrofolate reductase inhibitors as novel drugs that inhibit RUNX1-RUNX1T1-associated gene expression and induce cellular differentiation and ultimately apoptosis. Another study matched the signature of the nuclear factor-kB inhibitor parthenolide with a library of drug signatures and identified two novel agents that, similarly to parthenolide, eradicated primary AML stem cells and progenitor cells in functional assays. 69 Finally, a recent study reported an alternative, less biased strategy for the identification of novel drugs and drug targets in AML (Figure 4) . In this study, Marstrand et al. 70 identified signatures of deregulated genes in a subtype of AML, namely APL, by comparison of gene expression profiles from APL cells and their normal counterparts, that is promyelocytes, purified form healthy subjects. Subsequently, APL signatures were applied to a series of computational analyses including an in silico screen of the Connectivity MAP drug signature database. 71 These analyses led to the finding that APL cells exhibit stem cell properties in terms of gene expression and transcriptional regulation, and importantly identified novel candidate drugs and targets for therapeutic interventions. 70 Significantly, the identified candidate drugs including a histone deacetylase inhibitor (trichostatin A), an inhibitor of phosphoinositide 3-kinase (PI3K) (LY294002), and an inhibitor of phospholipase A2 (PLA2) (quinacrine), were all shown to inhibit proliferation and induce apoptosis of a human APL cell line (NB4).
Collectively, the above studies hold great promise that GEPbased genomic strategies can be used to prospectively define the most effective drug combinations for individual AML patients on a rational basis.
GEPFlink with other 'omics' screenings
During the next years, integration of GEP data with other 'omics' data like genomic, epigenomic and proteomic data holds great promise that 'omics' technologies will continue to contribute to improve the understanding of leukemia biology. For example, recent studies showed that deregulated miRNA expression has an important role in leukemogenesis, 72 and in accordance with GEP large-scale genome-wide miRNA profiling revealed miRNA expression profiles characteristic for cytogenetic subclasses, 73, 74 as well as molecular genetic subclasses like AML with CEBPA and NPM1 mutations or deregulated MN1 expression. 73, 75, 76 However, correlative studies intersecting GEP and miRNA expression profiling have been limited as it was thought that miRNAs mainly act via translational inhibition. In this study, the recent observation that miRNAs primarily affect changes in mRNA levels as well as protein levels by destabilization of target mRNAs rather than translational inhibition, provides new avenues for combining the information from miRNA and GEP studies. 77 With regard to 'omics' other than transcriptomics, genomewide array CGH and/or single nucleotide polymorphism analyses have revealed a large number of leukemia-specific copy number alterations (CNAs) as well as acquired homozygosity in the form of segmental uniparental disomy (UPD). 78 Parallel analysis of GEP and array CGH/single nucleotide polymorphism-defined CNAs has facilitated delineation of candidate genes in the respective genomic regions, as for example, demonstrated in AML with complex aberrations. 79 In contrast to ALL, the analysis of CNAs in AML has yielded only a small number of CNAs in most genomes of adult and pediatric AML patients, and the spectrum of AML-associated CNAs seems to be mainly non-recurrent. [80] [81] [82] These findings collectively illustrate the enormous genetic heterogeneity of AML and suggest that the potential of the extensive catalogs of CNAs might be better exploited by future integrative analyses.
Similarly, first comprehensive genome-wide promoter DNA methylation profiling studies in AML demonstrated that cytogenetic and molecular genetic subclasses harbor distinct methylation patterns, but also seem to share a 'common' DNA methylation pattern, which can be intersected with aberrant gene expression. 83 Although there are numerous additional studies providing evidence for the role of aberrant DNA methylation in AML, 84 first integrative studies also provided evidence that for example, an outcome predictor based on the combined DNA methylation and gene expression information can outperform predictors based solely on DNA methylation patterns or GEP. 85 In this study, future efforts combining analyses of various types of epigenetic modifications and GEP in AML will provide additional insights. 86 Finally, proteomic approaches have been used to address several essential questions in normal and malignant haematopoiesis including studies on drug response and survival of AML patients. [87] [88] [89] [90] [91] [92] [93] In this study, integrative approaches are important, as mRNA expression does not always correlate with protein expression levels due to for example, mRNA instability, posttranscriptional regulation, translation initiation and protein stability. 94, 95 Moreover, mRNA splice variants and post-translational modifications, which cannot be directly detected by microarray platforms based on 3 0 IVT (in-vitro transcription)-labeling protocols, can influence several critical parameters controlling the resulting protein function, including protein localization, protein activity, interaction with other molecules (for example, other proteins, nucleic acids and lipids) and turnover. As most cell phenotypes can be ascribed to protein expression levels and activities/interactions, combined characterization of AML phenotypes by GEP and proteomic analysis is clearly necessary for a full understanding of normal and diseasespecific biological processes, as well as how the proteome is reflected by the transcriptome. Furthermore, as most targeted therapeutics applied in the clinic are designed to interact with specific proteins (for example, topoisomerase I/II inhibitors, ABL1 kinase inhibitors, FLT3 inhibitors, VEGFR inhibitors, EGFR inhibitors, protease inhibitors and so on), a critical component of small molecule drug discovery and validation (including target specificity, resistance mechanisms) is the investigation of the proteome within the context of the transcriptome. For example, a first large proteomics study in primary AML samples used reverse-phase protein arrays to detect expression and posttranslational modification (phosphorylation) of 51 proteins in a cohort of 256 AML patients. 92 Proteomic profiling allowed the identification of patterns associated with the cellular phenotype, cytogenetic aberrations and patient outcome. In contrast, a recent study combining GEP and proteomic analysis to investigate embryonic stem cell differentiation into hematopoietic cells showed little correlation among differentially expressed mRNA transcripts and corresponding nuclear proteins. 88 This demonstrates that modulation of transcription does not directly affect levels of many nuclear proteins, and supports the need for systematic studies combining proteome and transcriptome analyses.
For the future, the challenge remains to discover the pertinent proteomic alterations, which determine the phenotypic changes identified by GEP studies. Although changes in expression of a particular mRNA transcript may not correlate with similar modulation of the corresponding protein expression or activity, it may be possible to integrate GEP and protein profiling data to define a set of transcripts (that is a gene expression signature), whose alteration corresponds to meaningful changes at the protein level and activity. In this sense, hierarchical clustering of GEP data might be used to guide development of more focussed proteomic profiling strategies, which will greatly reduce analysis time and cost. Alternatively, proteomics may eventually be used to guide development of more specific GEP approaches. It is evident that strategies, utilizing both GEP and other 'omics' profiling, will further elucidate clinically relevant modulation of specific cellular pathways/functions allowing us to understand and exploit differences between normal and disease-specific processes and phenotypes. Combination of these powerful methodological approaches might also be fundamental for the development of more efficacious therapeutic regimens.
Conclusions/perspectives
The vast genetic heterogeneity and variable clinical responses among MDS/AML patients is only partially explained by current cytogenetic and molecular genetic diagnostics, as these technologies do not provide diagnostic information at the genomic level. Hence, implementation of genomics technologies is needed to further improve the current World Health Organization classification system of MDS/AML, and most importantly to develop more effective therapies to specifically treat distinct subclasses of MDS/AML or, optimally, individual patients.
Microarray-based GEP as well as new technologies such as exon microarrays and the large-scale implementation of next generation sequencing will provide additional insights into the altered transcriptome in MDS/AML with regard to for example, alternative splice variants as well as 3 0 mRNA modifications leading to altered mRNA stability and miRNA processing. 96 Nevertheless, despite the robustness and high reproducibility of GEP-derived findings it remains questionable whether microarray-based GEP will have an important role in the diagnosis of MDS, and AML and whether it might be implemented to the clinic in the near future. With the notable exception of the MILE study, 16 so far there has been a relative paucity of other prospective and confirmatory studies, although recent studies performed within large AML study groups also suggest the potential clinical usefulness of GEP. 17, 18 Although critics might state a lack of clear-cut advantages in comparison with standard cytogenetic and molecular genetic diagnostics, GEP-based diagnostic platforms might be useful for the identification of patients with masked fusion proteins (like t(15;17) and t(8;21)) that are not detected by conventional cytogenetics or fluorescence in situ hybridization. 97, 98 In addition, GEP-based diagnostic platforms can provide information comparable to that of multiple different cytogenetic and molecular genetic analysis within a single experiment. Thus, a fully integrated and robust microarray platform such as the AMLprofiler, which is currently evaluated within a prospective clinical trial, might deliver faster results and improve patient classification by allowing determination of the presence of t(8;21), t(15;17), inv (16) , CEBPA double mutants, NPM1 mutations, as well as high expression levels of genes that recently have been shown to predict poor outcome (that is MECOM (EVI1), MN1, BAALC and ERG) within a single test (Skyline Diagnostics, Rotterdam, Netherlands http://www.amlprofiler.com/site/). 75, 99, 100 Future developments like the AMLprofiler might help overcome the current lack of therapeutic consequences even in MDS/AML cases, where microarray-based classifiers could improve classification or prognostication provided future research efforts can define and validate robust surrogates for the respective leukemia classes.
However, the question remains why some genomic aberrations can be easily detected by class prediction, whereas others are more difficult to predict. Supposedly, some genetic aberrations such as t(15;17), t(8;21) or inv (16) are 'drivers' (that is primary events) of the leukemic phenotype and therefore, most likely have a strong effect on gene regulation and can dramatically change a cell's transcriptome. In accordance, NPM1 and CEBPA mutations display distinct signatures, whereas FLT3 mutations likely represent 'passengers' (that is secondary events) that occur in combination with many other genetic aberrations and thus, are more difficult to detect based on expression patterns due to more prominent overlying 'driver' signatures. Furthermore, yet unknown hits and FLT3 aberrations might both result in the deregulation of an identical tyrosine kinase-signaling cascade thereby hampering the possibility for an accurate discrimination. And finally, there is evidence that gene expression profiles also depend on patient age, lineagespecificity and maturation stage of the leukemic cells, and the leukemic cell of origin. For example, leukemias arising from committed hematopoietic progenitor cells (HPCs) versus HSCs following transformation with the oncogenic fusion gene MLL-AF9, display significantly different gene expression signatures pointing to the different origin. 101 However, part of these current challenges might be solved by (i) future studies applying unbiased whole-genome transcriptome sequencing and large combined data sets that will allow the molecular heterogeneity of AML to be taken into account, and (ii) by studies comparing pediatric and adult AMLs and investigating for example, age and cell of origin-dependent differences.
With regard to the impact of GEP on further deciphering leukemia biology and discovering both novel drugs and druggable targets, GEP data will need to be integrated with genomic, epigenomic and proteomic data, and correlated with clinical information. In this study, new systems biology approaches combining various 'omics'Ftechnologies continue to contribute to the exploration of MDS and AML. Furthermore, data from functional screens will need to be taken into account, as for example, RNA interference screens can reveal novel disease mechanisms, such as non-oncogene addiction. 102 In addition, most of the current studies in MDS and AML have been performed with 'bulk' tumor material. In order to even better understand the pathomechanisms of MDS/AML, sophisticated analyses of prospectively purified tumor subpopulations such as leukemic stem cells might shed additional light on the molecular basis of MDS/AML. 103 Finally, future analyses will also need to focus on the influence of the tumor microenvironment on gene expression profiles in MDS/AML, as there is accumulating evidence of the utmost importance of the stem cell niche, despite it being yet poorly understood. 104 Ultimately, GEP will continue to contribute to an improved understanding of the complex nature underlying MDS and AML. However, the vast complexity of GEP-based data requires large studies/cohorts to obtain valid data of clinical significance, and these will only be feasible by combining future efforts within well-structured leukemia research networks such as the above mentioned COST initiative and the ELN.
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